Literature DB >> 11146697

The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life.

C Farup1, L Kleinman, S Sloan, D Ganoczy, E Chee, C Lee, D Revicki.   

Abstract

BACKGROUND: Two types of reflux episodes have been identified: upright or daytime and supine or nocturnal. The population-based prevalence of symptoms of nocturnal gastroesophageal reflux disease (GERD) and the impact of those symptoms on health-related quality of life (HRQL) have not been established.
METHODS: A national random-sample telephone survey was conducted to estimate the prevalence of frequent GERD and nocturnal GERD-like symptoms and to assess the relationship between HRQL, GERD, and nocturnal GERD symptoms. Respondents were classified as controls, subjects with symptomatic nonnocturnal GERD, and subjects with symptomatic nocturnal GERD. The HRQL was assessed using the Medical Outcomes Study Short-Form 36 Health Survey (SF-36).
RESULTS: The prevalence of frequent GERD was 14%, with an overall prevalence of nocturnal GERD of 10%. Seventy-four percent of those with frequent GERD symptoms reported nocturnal GERD symptoms. Subjects with nonnocturnal GERD had significant decrements on the SF-36 physical and mental component summary scores compared with the US general population. Subjects reporting nocturnal GERD symptoms were significantly more impaired than subjects reporting nonnocturnal GERD symptoms on both the physical component summary (38.94 vs 41. 52; P<.001) and mental component summary (46.78 vs 49.51; P<.001) and all 8 subscales of the SF-36 (P<.001). Subjects with nocturnal GERD demonstrated considerable impairment compared with the US general population and chronic disease populations. Subjects with nocturnal GERD had significantly more pain than those with hypertension and diabetes (P<.001) and similar pain compared with those with angina and congestive heart failure.
CONCLUSIONS: Nocturnal symptoms are commonly experienced by individuals who report frequent GERD symptoms. In addition, HRQL is significantly impaired in those persons who report frequent GERD symptoms, and HRQL impairment is exacerbated in those who report nocturnal GERD symptoms.

Entities:  

Mesh:

Year:  2001        PMID: 11146697     DOI: 10.1001/archinte.161.1.45

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  72 in total

1.  The value of branded proton pump inhibitors: formulary considerations.

Authors:  David A Peura; Rosemary R Berardi; Javier Gonzalez; Louis Brunetti
Journal:  P T       Date:  2011-07

Review 2.  Quality of life assessment in gastro-oesophageal reflux disease.

Authors:  E J Irvine
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

3.  Management of nighttime gastroesophageal reflux disease.

Authors:  William C Orr
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-08

4.  Bravo pH Testing On and Off Treatment With Immediate-Release Omeprazole: A Review of Findings Presented at the 71st Annual Scientific Meeting of the American College of Gastroenterology October 20-25, 2006 Las Vegas, Nev.

Authors:  Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-01

5.  Gastroesophageal reflux disease: Important considerations for the older patients.

Authors:  Maxwell M Chait
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

6.  Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study.

Authors:  Anna Rydén; Mona Martin; Katarina Halling; Anna Niklasson
Journal:  Patient       Date:  2013       Impact factor: 3.883

Review 7.  Gastroesophageal reflux disease and sleep disturbances.

Authors:  Yasuhiro Fujiwara; Tetsuo Arakawa; Ronnie Fass
Journal:  J Gastroenterol       Date:  2012-05-17       Impact factor: 7.527

8.  Evaluation and management of dyspepsia.

Authors:  R Christopher Harmon; David A Peura
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

9.  A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms.

Authors:  Edoardo G Giannini; Patrizia Zentilin; Pietro Dulbecco; Elena Iiritano; Claudio Bilardi; Edoardo Savarino; Carlo Mansi; Vincenzo Savarino
Journal:  Dig Dis Sci       Date:  2006-09-15       Impact factor: 3.199

Review 10.  Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs.

Authors:  J Dent; D Armstrong; B Delaney; P Moayyedi; N J Talley; N Vakil
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.